139 related articles for article (PubMed ID: 38305404)
1. Design, Virtual Screening, Molecular Docking, ADME and Cytotoxicity Studies of 1,3,5-Triazine Containing Heterocyclic Scaffolds as Selective BRAF Monomeric, Homo and Heterodimeric Inhibitors.
Singh AK; Sreelakshmi P; Pathak P; Kumar A; Singh H; Yadav JP; Verma A; Grishina M; Kumar P
Comb Chem High Throughput Screen; 2024 Jan; ():. PubMed ID: 38305404
[TBL] [Abstract][Full Text] [Related]
2. The first small molecules capable of strongly suppressing proliferation of cancer cells harboring BRAF class I/II/III mutations.
Choi SH; Shin I; Kim N; Nam Y; Sim T
Biochem Biophys Res Commun; 2020 Nov; 532(2):315-320. PubMed ID: 32873393
[TBL] [Abstract][Full Text] [Related]
3. Challenges and Opportunities in the Crusade of BRAF Inhibitors: From 2002 to 2022.
Singh AK; Sonawane P; Kumar A; Singh H; Naumovich V; Pathak P; Grishina M; Khalilullah H; Jaremko M; Emwas AH; Verma A; Kumar P
ACS Omega; 2023 Aug; 8(31):27819-27844. PubMed ID: 37576670
[TBL] [Abstract][Full Text] [Related]
4. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
[TBL] [Abstract][Full Text] [Related]
5. Dabrafenib for the treatment of BRAF V600-positive melanoma: a safety evaluation.
Rutkowski P; Blank C
Expert Opin Drug Saf; 2014 Sep; 13(9):1249-58. PubMed ID: 25014231
[TBL] [Abstract][Full Text] [Related]
6. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.
Dankner M; Rose AAN; Rajkumar S; Siegel PM; Watson IR
Oncogene; 2018 Jun; 37(24):3183-3199. PubMed ID: 29540830
[TBL] [Abstract][Full Text] [Related]
7. A Rare p.T599dup BRAF Mutant NSCLC in a Non-Smoker.
Turshudzhyan A; Vredenburgh J
Curr Oncol; 2020 Dec; 28(1):196-202. PubMed ID: 33704186
[TBL] [Abstract][Full Text] [Related]
8. RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling.
Yao Z; Gao Y; Su W; Yaeger R; Tao J; Na N; Zhang Y; Zhang C; Rymar A; Tao A; Timaul NM; Mcgriskin R; Outmezguine NA; Zhao H; Chang Q; Qeriqi B; Barbacid M; de Stanchina E; Hyman DM; Bollag G; Rosen N
Nat Med; 2019 Feb; 25(2):284-291. PubMed ID: 30559419
[TBL] [Abstract][Full Text] [Related]
9. BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors.
Schreck KC; Grossman SA; Pratilas CA
Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31466300
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel natural drug candidates against BRAF mutated carcinoma; An integrative in-silico structure-based pharmacophore modeling and virtual screening process.
Dain Md Opo FA; Alsaiari AA; Rahman Molla MH; Ahmed Sumon MA; Yaghmour KA; Ahammad F; Mohammad F; Simal-Gandara J
Front Chem; 2022; 10():986376. PubMed ID: 36267655
[TBL] [Abstract][Full Text] [Related]
11. Novel and Potent Small Molecules against Melanoma Harboring BRAF Class I/II/III Mutants for Overcoming Drug Resistance.
Kim N; Shin I; Lee J; Jeon E; Kim Y; Ryu S; Ju E; Cho W; Sim T
Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33917428
[TBL] [Abstract][Full Text] [Related]
12. Network indirect comparison of 3 BRAF + MEK inhibitors for the treatment of advanced BRAF mutated melanoma.
Consoli F; Bersanelli M; Perego G; Grisanti S; Merelli B; Berruti A; Petrelli F
Clin Transl Oncol; 2020 Jun; 22(6):900-907. PubMed ID: 31555967
[TBL] [Abstract][Full Text] [Related]
13. Combined RAF and MEK Inhibition to Treat Activated Non-V600 BRAF-Altered Advanced Cancers.
Rustgi N; Maria A; Toumbacaris N; Zhao H; Kargus K; Bryant M; Waksmundzki A; Aricescu I; Lefkowitz RA; Li BT; Chou J; Capanu M; de Stanchina E; Misale S; Shia J; Yaeger R
Oncologist; 2024 Jan; 29(1):15-24. PubMed ID: 37616543
[TBL] [Abstract][Full Text] [Related]
14. Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy.
Rajkumar S; Berry D; Heney KA; Strong C; Ramsay L; Lajoie M; Alkallas R; Nguyen TT; Thomson C; Ahanfeshar-Adams M; Dankner M; Petrella T; Rose AAN; Siegel PM; Watson IR
Cell Rep; 2022 Apr; 39(1):110634. PubMed ID: 35385748
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Dabrafenib and Trametinib in a Patient with Squamous-Cell Carcinoma, with Mutation p.D594G in
Grenda A; Krawczyk P; Targowska-Duda KM; Kieszko R; Paśnik I; Milanowski J
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674722
[TBL] [Abstract][Full Text] [Related]
16. Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor.
Seghers AC; Wilgenhof S; Lebbé C; Neyns B
Melanoma Res; 2012 Dec; 22(6):466-72. PubMed ID: 22584957
[TBL] [Abstract][Full Text] [Related]
17. Triplet combination of BRAF, MEK and PD-1/PD-L1 blockade in melanoma: the more the better?
Trojaniello C; Vitale MG; Ascierto PA
Curr Opin Oncol; 2021 Mar; 33(2):133-138. PubMed ID: 33399314
[TBL] [Abstract][Full Text] [Related]
18. Encorafenib plus binimetinib in patients with
Riely GJ; Ahn MJ; Felip E; Ramalingam SS; Smit EF; Tsao AS; Alcasid A; Usari T; Wissel PS; Wilner KD; Johnson BE
Future Oncol; 2022 Mar; 18(7):781-791. PubMed ID: 34918546
[TBL] [Abstract][Full Text] [Related]
19. Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma.
Rose AAN
Drugs Today (Barc); 2019 Apr; 55(4):247-264. PubMed ID: 31050693
[TBL] [Abstract][Full Text] [Related]
20. Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.
Noeparast A; Teugels E; Giron P; Verschelden G; De Brakeleer S; Decoster L; De Grève J
Oncotarget; 2017 Sep; 8(36):60094-60108. PubMed ID: 28947956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
